McGuff Pharmaceuticals (MPI) has received FDA approval for the construction of a new technologically advanced facility at 4040 West Carriage Drive in Santa Ana, California. This facility is is a 86,000 square-foot sterile fill-and-finish pharmaceutical manufacturing plant, which will allow MPI to meet the growing demands of its customers.

This new facility is designed to meet customer demand for MPI NDA and ANDA labelled injectable products, contract manufactured products and clinical trial products. Following the approval, the company will increase its production of ASCOR, an FDA-approved Ascorbic Acid Injection (vitamin C injection).

As a CMO/CDMO, MPI supports pharmaceutical companies in introducing new products or formulas to the market without investing in additional infrastructure to support it. MPI provides end-to-end, fully integrated drug development and manufacturing solutions and services, including formulation development, product stability, regulatory compliance, clinical trials, quality assurance, and more.